News

Professor Mohamed Ayman Ashour, Minister of Higher Education and Scientific Research, has issued a ministerial decree to renew confidence in Prof. Ahmed Mohamed Abdel Aziz Hassan

The memorandum of understanding aims to involve Theodor Bilharz Research Institute and Badr University in working to create a new generation of researchers in the medical and health fields who seek scientific progress without compromising environmental elements. Theodor Bilharz Research Institute is the largest of its kind in Egypt and the region in the field of scientific research, and the training and research tools available to both parties to achieve this goal and qualify outstanding young people who are familiar with the objectives of specialized knowledge and skills within a framework of equality, joint cooperation, and the exchange of special privileges between the two parties.

In a step that reflects the national direction toward institutional integration and the strengthening of efforts to combat endemic diseases, Theodor Bilharz Research Institute (TBRI), under the patronage of Prof. Ahmed Abdel Aziz, Director and Chairman of the Institute, held an advanced training course entitled: "Enhancing Diagnostic Capabilities for Schistosomiasis."

In a scientific achievement that adds to the record of research successes of  Theodor Bilharz Research Institute, the Egyptian Intellectual Property Authority has approved a patent submitted to the Patent Office, funded by the Science, Technology, and Innovation Funding Authority (STDF), in the field of producing genetically engineered therapeutic proteins using biotechnology.

Professor Ahmed Abdel Aziz, Acting Director of TBRI and Chairman of the Board of Directors, extends his sincere congratulations to Professor Mohamed Ali Saber, Professor in the Department of Biochemistry and Molecular Biology, and Professor Ehab El-Dabaa, Deputy Head of the Division of Biochemistry, Molecular Biology, and Medicinal Chemistry, on the occasion of obtaining a patent from the Science, Technology & Innovation Funding Authority (STDF) in the field of producing genetically engineered therapeutic proteins using biotechnology.